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INTRODUCTION
Advancements in treating autoimmune diseases such as multiple 
sclerosis (MS) have been made by enhancing our understanding 
of the molecular processes involved in disease progression.1,2 The 
complexity of immune responses and the heterogeneous nature 
of immune cells complicate the design of therapeutics. In the 
case of relapsing-remitting MS, the disease state is propagated 
through professional antigen-presenting cells, stimulating the 
clonal expansion and activation of T cells recognizing endogenous 
autoantigen(s) resulting in subsequent attack(s) on the central ner-
vous system and neural degeneration.3–5 The majority of current US 
Food and Administration (FDA)–approved therapies for MS focus on 
suppressing disease symptoms through inhibition of the immune 
inflammatory response.6–8 In fact, most therapeutics may manage 
disease symptoms, but are broadly immunosuppressive, often lead-
ing to substantial side effects.9
“Antigen-specific immunotherapies” (antigen-SITs) aim to repro-
gram the immune response, which is the root cause of many auto-
immune diseases.10 An FDA-approved MS therapy, Copaxone (R) 
(Teva Neuroscience, Kansas City, MO), utilizes an antigen-specific 
approach using polymeric antigen derived from myelin basic pro-
tein in an effort to promote tolerance by inducing antigen-specific 
regulatory T cells.11–13 Although the mechanisms of Copaxone (R) 
are still under active investigation, it has been shown to improve 
clinical outcomes in patients and in animal models of MS such as 
experimental autoimmune encephalomyelitis (EAE).14
Further therapeutic enhancement of antigen-SITs may be achieved 
by codelivering another active molecular signal (i.e., adjuvant). 
Vaccines provide an interesting parallel to the concept of adjuvanted 
antigen-SITs. In traditional vaccines, antigen presentation and recog-
nition result in immune protection through use of adjuvanted formu-
lations.15–18 Protection is achieved by presenting antigen with a sec-
ond proinflammatory “context” signal to direct appropriate protective 
immune responses. Administration of antigens without adjuvant can 
also induce immune tolerance. For example, frequent low doses of 
soluble antigen have been used to induce tolerance in patients to 
treat specific allergies.19–22 Both vaccine and antigen-SIT approaches 
are “antigen specific;” however, the dose and the presence or absence 
of a “secondary” signal (e.g., vaccine adjuvant) drastically alter the 
response from proinflammatory to tolerogenic. Simultaneous pre-
sentation of antigen and another “secondary” (coinhibitory) signal 
using peptide conjugates has also been shown to skew the immune 
response toward tolerance.23–30 Thus, both antigen and codelivery of 
a secondary signal (i.e., adjuvant, immune cell inhibitor) are essential 
for determining the resultant immune response.31,32
History also provides some guidance for designing a molecular 
construct to codeliver antigen and a secondary signal. Beginning 
in 1976, Dintzis and others systematically studied a wide range of 
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Autoimmune diseases such as multiple sclerosis (MS) are typified by the misrecognition of self-antigen and the clonal expansion of 
autoreactive T cells. Antigen-specific immunotherapies (antigen-SITs) have long been explored as a means to desensitize patients 
to offending self-antigen(s) with the potential to retolerize the immune response. Soluble antigen arrays (SAgAs) are composed 
of hyaluronic acid (HA) cografted with disease-specific autoantigen (proteolipid protein peptide) and an ICAM-1 inhibitor peptide 
(LABL). SAgAs were designed as an antigen-SIT that codeliver peptides to suppress experimental autoimmune encephalomyelitis 
(EAE), a murine model of MS. Codelivery of antigen and cell adhesion inhibitor (LABL) conjugated to HA was essential for SAgA 
treatment of EAE. Individual SAgA components or mixtures thereof reduced proinflammatory cytokines in cultured splenocytes 
from EAE mice; however, these treatments showed minimal to no in vivo therapeutic effect in EAE mice. Thus, carriers that code-
liver antigen and a secondary “context” signal (e.g., LABL) in vivo may be an important design criteria to consider when designing 
antigen-SIT for autoimmune therapy.
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polymers with grafted “haptens” (e.g., antigens) and developed 
a set of rules for inducing immune stimulation or tolerance.33,34 
“Dintzis Rules” proposed that characteristics such as polymer size, 
solubility, flexibility, antigen valency, spacing, and binding avidity 
are necessary to direct the immune response. Of particular inter-
est, carriers under 100 kDa could be tolerogenic and, depending 
on hapten density, could target or induce a subset of immune cells 
(T cells or B cells) directly.35–37 Such thinking prompted rational 
design of graft polymers that simultaneously display multiple cop-
ies of antigen and a secondary “context” signal that could inhibit 
costimulation.
Here, Dintzis Rules (polymers < 100 kDa displaying ~1–2 antigens 
per 1,000 kDa) were combined with the concept of utilizing this 
carrier to codeliver antigen and an immune cell adhesion inhibitor, 
which was previously shown to suppress EAE, a murine model of 
MS.38 Soluble antigen arrays (SAgAs) were synthesized by cograft-
ing a known MS autoantigen derived from proteolipid protein 
amino acids 139–151 (proteolipid protein peptide (PLP)) and an 
intercellular adhesion molecule 1 (ICAM-1) inhibitor peptide (LABL, 
ITDGEATDSG) to hyaluronic acid (HA) via a single-step grafting tech-
nique (Table 1).38 Once efficacy was demonstrated, SAgA contain-
ing both grafted peptides (SAgAPLP:LABL) was compared to a variety 
Table 1 Sample identification, peptide concentration, and number of peptides per HA (16.9 kDa) chain as determined by HPLC
Sample PLP conc. (nmol) LABL conc. (nmol) Final ratio Number of peptides per HA polymer
SAgAPLP:LABL 
275 325 1.2:1 11:10 (LABL:PLP)
HALABL   
— 462 N/A 15
HAPLP   
286 — N/A 11
The peptide concentrations were calculated based on HPLC analysis of 1-mg complex. Results shown are an average from triplicate injections of a single batch 
preparation. All samples had a relative standard deviation (RSD) ≤0.01.
Conc., concentration; HA, hyaluronic acid; HALABL, HA with grafted LABL peptide; HAPLP, HA with grafted PLP peptide; HPLC, high-performance liquid chromatography; 
N/A, not applicable; PLP, proteolipid protein peptide; SAgA, soluble antigen array; SAgAPLP:LABL, SAgA cografted with PLP and LABL peptides.
Figure 1  Experimental autoimmune encephalomyelitis (EAE) is not affected by component mixture or hyaluronic acid (HA)-conjugate controls. EAE 
was induced in SJL mice (day 0) and were subsequently treated with (a,b) component mixture of HA, free proteolipid protein peptide (PLP), and 
free LABL peptides and (c,d) HA with grafted PLP peptide (HAPLP) and HA with grafted LABL peptide (HALABL) polymer controls on days 4, 7, and 10. 
All samples showed no statistical difference when compared with phosphate-buffered saline (PBS) control group. Data are expressed as mean ± SD, 
 n = 6 mice per group.
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of therapeutic controls to verify that disease suppression was due 
to simultaneous multivalent presentation of both antigen and cell 
adhesion signals. The effect of SAgAPLP:LABL on splenocytes isolated 
from EAE mice was also investigated and compared with in vivo 
treatment of EAE mice.
ReSUlTS
Characterization of polymeric SAgAs and HA graft control molecules
Peptides were manufactured using solid phase synthesis, and the 
HA polymer backbone was purchased from Lifecore. Gel perme-
ation chromatography and high-performance liquid chromatogra-
phy (HPLC) were used to characterize the manufactured peptides, 
the homopeptide graft polymer controls (HA with grafted LABL 
peptide (HALABL) and HA with grafted PLP peptide (HAPLP)), and the 
SAgAPLP:LABL as previously reported.
38 The expected shift in retention 
time was observed by gel permeation chromatography, suggesting 
an increase in molecular weight relative to the HA starting material, 
as compared with pullulan standards (see Supplementary Figure 
S1). A graphical representation of each of the prepared samples 
and the calculated amount of peptide grafted to the polymer deter-
mined by HPLC are shown in Table 1. HPLC data showed a consistent 
concentration of grafted peptides for all samples. Peptide concen-
tration was calculated based on analysis of 1-mg manufactured 
complex and comparison with a standard curve for the individual 
peptides. SAgAPLP:LABL samples had similar peptide concentration as 
HAPLP and HALABL controls, but the homopolymers displayed half the 
amount of total peptide as indicated by values in Table 1.
Codelivery of conjugated antigen and inhibitor represses EAE 
disease in vivo
A control component mixture (HA, free LABL, and free PLP), graft 
homopolymer controls (HALABL, HAPLP, and a 1:1 mixture of HALABL and 
HAPLP), and SAgAPLP:LABL were evaluated in the PLP:SJL/J mouse EAE 
model against a phosphate-buffered saline (PBS) negative control. 
All samples were dosed so that the concentration of PLP delivered 
was equal (200 nmol). A dose-ranging study supported the use of 
200 nmol of PLP (see Supplementary Figure S2). For HALABL samples, 
LABL peptide content was calculated to equal the LABL content in 
SAgAPLP:LABL (i.e., 200 nmol of LABL). Disease onset occurs ~10–12 days 
postimmunization. At this time, mice begin to show disease signs such 
as weakness, paralysis of their tail and limbs, and loss of body weight.
Disease was not altered in mice treated with the component mix-
ture, HALABL, or HAPLP homopolymer controls as indicated by clinical 
score and percent weight change (Figure 1a–d). In contrast, mice 
treated with a 1:1 mixture of HALABL and HAPLP homopolymers or 
the cografted SAgAPLP:LABL showed significant disease suppression 
(Figure 2). The SAgAPLP:LABL treatment significantly suppressed EAE 
(P < 0.05) in both score and percent weight change on days 11–17 
of the study, whereas the 1:1 homopolymer mixture of HALABL and 
HAPLP significantly inhibited disease (P < 0.05) on days 11–15. While 
the SAgAPLP:LABL treatment showed longer disease inhibition com-
pared with PBS, this treatment was not significantly different from 
the mixture of HAPLP and HALABL.
SAgAPLP:LABL treatment alters cellular metabolism and cytokine 
expression during peak of disease in an ex vivo PLP rechallenge 
model
In order to identify whether the in vivo protection afforded by 
SAgAPLP:LABL altered splenocyte population characteristics, cellular 
metabolism of harvested splenocytes was measured. To achieve 
this, mice were induced with EAE (clinical scoring data not shown), 
and splenocytes were isolated on day 12 (peak of disease) and 
day 25 (disease remission). Ex vivo stimulation studies of EAE sple-
nocytes isolated on day 12 or 25 suggested that the day 25 EAE 
splenocytes had a more robust response to PLP rechallenge. This 
is demonstrated by the statistical increase in metabolic and cyto-
kine values shown in Table 2. Therefore, the day 25 time point was 
used to identify whether SAgAPLP:LABL or control treatments could dif-
ferentially alter cellular metabolism and cytokine expression in PLP 
rechallenged EAE splenocytes.
The harvested splenocytes were then treated ex vivo and rechal-
lenged with 25 µmol/l PLP antigen or vehicle. Basal levels of cellular 
metabolism were not altered between SAgAPLP:LABL- and PBS-treated 
mice (Figure 3). Additionally, cellular metabolism was not further 
altered by the PLP rechallenge in all samples except HALABL, where 
PLP rechallenge resulted in a large increase in resazurin fluores-
cence reading (Figure 3).
In vitro cytokine profiling in SAgAPLP:LABL and conjugate control 
treated splenocytes
Whether the difference in cellular metabolism was coupled to cyto-
kine response in these splenocyte populations was explored next. 
In vitro cytokine levels were determined 120 hours posttreatment 
Figure 2 Codelivery of conjugated proteolipid protein peptide 
(PLP) antigen and conjugated LABL peptide improves experimental 
autoimmune encephalomyelitis (EAE) clinical outcomes. EAE was 
induced in SJL mice (day 0) and were subsequently treated with soluble 
antigen array cografted with PLP and LABL peptides (SAgAPLP:LABL) or a 
1:1 mixture of hyaluronic acid (HA) with grafted PLP peptide (HAPLP) and 
HA with grafted LABL peptide (HALABL) polymer controls on days 4, 7, and 
10. Daily (a) clinical scores (P < 0.05; days 11–17) and (b) percent weight 
change was determined (P < 0.05; days 11–17). Data are expressed as 




















1:1 HAPLP and HALABL
PBS
SAgAPLP:LABL
1:1 HAPLP and HALABL
PBS









Codelivery of antigen and LABL for efficacy of SAgAs in EAE
JO Sestak et al.
Molecular Therapy — Methods & Clinical Development (2014) 14008 © 2014 The American Society of Gene & Cell Therapy
by using bead array enzyme-linked immunosorbent assays (ELISAs). 
A total of nine cytokines showed significant differences between 
media treatment and SAgAPLP:LABL and control treatments. Treatment 
with HALABL significantly reduced basal and PLP-induced cytokine 
levels of all cytokines profiled, except for interleukin (IL)-2, which 
seemed to be not altered. For all other treatments, only SAgAPLP:LABL 
showed a significantly lower level of IL-4 as compared with the 
media, and no difference was seen in the level of IL-5. The data 
for IL-6 showed that while basal levels of IL-6 were elevated with 
sample treatment over media controls, levels after PLP rechallenge 
remained constant and were significantly decreased than that of 
rechallenged media control samples. Conversely, treatment with 
HALABL, the mixture of free HA and free peptides, and the mixture 
of HALABL and HAPLP significantly increased the levels of IL-2 in PLP 
restimulated samples as compared with the respective basal media 
control. The 1:1 mixture of HAPLP and HALABL showed significant 
increases in both the basal and restimulated samples.
Cytokines associated with allergic and autoimmune inflamma-
tory responses, IL-13, IL-17, IL-22, and tumor necrosis factor-α (TNF-
α), were also measured (Figure 4). Similar to our previous study, data 
for interferon-γ (IFN-γ) in PLP rechallenged splenocytes at day 25 
were above the maximum level of detection, and conclusions could 
not be drawn from the data set (see Supplementary Figure S2). In 
this set of cytokines, HALABL again showed significantly decreased 
levels compared with the media control even when rechallenged 
with PLP. For all other samples, a significant increase in basal levels 
of IL-13 and TNF-α was seen. Upon rechallenge with PLP, a significant 
decrease in IL-13 expression was seen when treated with the HALABL 
and HAPLP mixture and SAgAPLP:LABL. Similarly, increased levels of 
IL-22 were seen in all samples as compared with media basal levels; 
however, only the HALABL and HAPLP mixture provided a significantly 
decreased level of IL-22. The data suggested that HALABL represses 
and in most cases eliminates cytokine expression of most cytokines 
profiled. Furthermore, the data suggested that variations of peptide 
carriers can alter cytokine response in cultured EAE splenocytes.
DISCUSSION
It was rationalized that combining delivery of antigen with deliv-
ery of a secondary “context” signal, in this case a peptide known 
to inhibit immune cell adhesion, may synergize the effects of two 
discrete therapeutic approaches: presentation of antigen and inter-
ruption of cell signaling events. Much like vaccines, which codeliver 
antigen and immune-stimulatory adjuvant to illicit and immune 
response, it was theorized that codelivery of antigen and an inhibi-
tor of immune cell adhesion should reintroduce tolerance to the 
presented antigen, opening new opportunities to antigen-SITs. In 
this study, we evaluated SAgAs as novel antigen-SIT molecules that 
are covalently grafted with cell adhesion antagonists and the causal 
Table 2 Cellular metabolism and culture supernatant cytokine expression levels in EAE splenocytes were significantly higher at disease 
remission (day 25) than at peak of disease (day 12)
Isolation day 12 12 25 25
SAgAPLP:LABL  
ex vivo PLP 
stimulation
PBS SAgAPLP:LABL PBS SAgAPLP:LABL
Vehicle 25 µmol/l PLP Vehicle 25 µmol/l PLP Vehicle 25 µmol/l PLP Vehicle 25 µmol/l PLP
Resazurin 
(ex560/em590)
1,298 ± 244 3,885 ± 745** 2,012 ± 590 6,387 ± 396**,*** 7,432 ± 244* 7,212 ± 112 6,984 ± 325* 7,188 ± 161
IL-1α (pg/ml) 15 ± 5 15 ± 5 6 ± 4 15 ± 8 14 ± 5. 175 ± 26** 20 ± 8 198 ± 25**
IL-2 (pg/ml) 13 ± 6 46 ± 22 20 ± 8 221 ± 55** 100 ± 23* 276 ± 112 75 ± 4 154 ± 65
IL-4 (pg/ml) ND 66 ± 22 13 ± 4 85 ± 15** 18 ± 3 130 ± 10** 23 ± 8 141 ± 9**
IL-5 (pg/ml) ND ND ND 17 ± 11 17 ± 11 102 ± 9 ND 123 ± 10
IL-6 (pg/ml) 148 ± 131 89 ± 26 44 ± 30 518 ± 155**,*** 17 ± 7 627 ± 112** 33 ± 5 623 ± 147**
IL-10 (pg/ml) ND 9 ± 4 ND ND ND 81 ± 12 ND 93 ± 12
IL-13 (pg/ml) ND 77 ± 67 ND 1,505 ± 615*** 591 ± 461 4,305 ± 678** 494 ± 261 4,067 ± 1,041**
IL-17 (pg/ml) ND 46 ± 12 ND 524 ± 236 686 ± 657 1,833 ± 1,017 208 ± 105 1,840 ± 580
IL-21 (pg/ml) ND ND ND ND ND 64 ± 15 ND 60 ± 17
IL-22 (pg/ml) ND 45 ± 32 ND 54 ± 10 415 ± 323 1,713 ± 562** 538 ± 275 1,756 ± 243
IL-27 (pg/ml) ND ND ND ND ND 394 ± 54 ND 444 ± 47
IFN-γ (pg/ml) ND 83 ± 24 ND 699 ± 161**,*** 120 ± 62 ≥20,000** 279 ± 108 ≥20,000**
TNF-α (pg/ml) 66 ± 24 110 ± 29 14 ± 5*(P = 0.06) 160 ± 24** 191 ± 61 247 ± 30 274 ± 95* 288 ± 6
GM-CSF (pg/ml) 42 ± 26 61 ± 39 64 ± 26 243 ± 56** 122 ± 11 543 ± 74** 64 ± 37 513 ± 110**
Primary splenocytes were isolated from EAE mice treated with SAgAPLP:LABL or vehicle (PBS) during peak of disease (day 12) or disease remission (day 25). Splenocytes 
were stimulated with 25 µmol/l PLP or vehicle for 120 hours, and culture supernatant was collected. For cellular metabolism rates, cells were then incubated with 
resazurin (75 µmol/l final), and fluorescence (ex560/em590) was determined 24 hours later. Data are expressed as mean ± SEM, n = 4–6 mice per group.
*Indicates significance (P ≤ 0.05) from untreated day 12 splenocytes treated with PBS in vivo. **Indicates significance (P ≤ 0.05) from respective unstimulated 
splenocytes. ***Indicates significance (P ≤ 0.05) from unstimulated EAE splenocytes isolated from vehicle treated mice during respective disease day.
EAE, experimental autoimmune encephalomyelitis; ex560/em590, 560excitation/590emission; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; 
IL, interleukin; ND, not detectable; PBS, phosphate-buffered saline; PLP, proteolipid protein peptide; SAgA, soluble antigen array; SAgAPLP:LABL, SAgA cografted with 
PLP and LABL peptides; TNF, tumor necrosis factor.
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disease antigen, PLP, for treatment of EAE in mice, a murine model 
for MS.
In MS and animal models such as EAE, destruction of myelin in 
the central nervous system is propagated at least in part by CD4+ 
T cells.8,14,39 Current antigen-SITs focus on treating MS through 
modification of antigen via peptide constructs. Altered peptide 
ligands,40–43 splenocytes coupled with myelin basic protein or PLP-
derived peptides,44,45 soluble PLP139–151: major histocompatibility 
complex receptor construct,46 and the FDA-approved synthetic 
copolymer glatiramer acetate (Copaxone (R)), look to generate a 
Th2 response and/or induce tolerance through “regulatory” T cells 
due to altered recognition of modified antigen.47–49
Alternatively, non–antigen-SITs seek to disrupt molecular signal-
ing or cell adhesion events via monoclonal antibodies such as anti-
CD28 Fab,50 anti-CD40L antibody,51 and the FDA-approved natali-
zumab marketed as TYSABRI (R) (biogen idec, Cambridge, MA), an 
anti-α4 integrin antibody.52 By impeding a secondary “context” sig-
nal such as costimulation or immune cell adhesion, events such as 
the formation of the immunological synapse, the interface between 
professional antigen-presenting cells and T cells, can be prevented 
prohibiting the activation of CD4+ T cells or lymphocyte recruit-
ment.23,53 Unfortunately, general inhibition of events such as cell 
adhesion can have unwanted and disastrous immunosuppressive 
effects.14,52 While both antigen-SIT and secondary “context” signal 
interruption provide some therapeutic benefit, combining both the 
approaches could potentially enhance antigen-SIT efficacy, offering 
the specificity that is lacking in global disruption of secondary “con-
text” signals.
Our previous studies found that HA conjugated to both PLP 
autoantigen and LABL inhibitory peptide (SAgAPLP:LABL) suppressed 
EAE, but a mixture of unconjugated HA and free peptides did not, 
suggesting that conjugation of these peptides is required for 
autoimmune protection in vivo. The need for simultaneous deliv-
ery of both signals on the SAgA construct was further investigated 
by testing a 1:1 mixture of HALABL and HAPLP. The 1:1 mixture pro-
tected mice from EAE to an extent similar to that of SAgAPLP:LABL; 
however, mice given equivalent doses of HALABL or HAPLP indepen-
dently did not improve disease outcomes in EAE mice. This result 
is strikingly similar to other approaches requiring conjugation for 
codelivery of antigen and immune inhibitor in other models of 
autoimmunity.54–56
Because the immune system is highly mobile, dynamic, and 
poorly understood, a tremendous challenge is present when try-
ing to screen immune therapies. Therefore, we explored an ex 
vivo model using cellular viability and cytokine production as end 
points to systematically screen immunomodulatory compounds. 
Stimulated splenocytes from EAE mice were used to explore param-
eters such as signaling events initiated by SAgAs. Splenocytes col-
lected at day 12 showed dramatic increase in cytokine expression 
levels of IL-2, IL-5, IL-6, IL-13, IL-22, TNF-α, and IFN-γ in PLP rechal-
lenged splenocytes treated with SAgAPLP:LABL (Table 2). Although 
the cytokine expression was more robust at day 25 in response to 
PLP rechallenge, there was no difference in cytokine expression 
levels between SAgAPLP:LABL and PBS treatment (Table 2). This may 
suggest that many of the PLP-reactive splenocytes migrated out 
of the spleen by day 12 and that SAgAPLP:LABL may help “sequester” 
PLP-reactive cells within the spleen, thus limiting the potential pool 
of myelin-damaging lymphocytes in the periphery. Supporting 
this hypothesis is the qualitative observation that during peak of 
disease, EAE mice treated with PBS had extremely small spleens 
and splenocyte recovery was ~25% less compared with EAE mice 
treated with SAgAPLP:LABL or healthy matched control mice (data 
not shown). Alternatively, several of these cytokines (TNF-α, IFN-γ, 
and IL-6) have been shown to protect against EAE, suggesting that 
SAgAPLP:LABL-dependent induction of these cytokines may be protec-
tive in this model; however, these cytokines have been shown to 
promote damaging inflammation in EAE studies.57,58
Several cytokines induced by PLP rechallenge were signifi-
cantly reduced by various treatments involving the conjugation of 
HA:PLP:LABL. Ex vivo cytokine expression, however, did not corre-
late to in vivo clinical responses. When examined using ex vivo EAE 
splenocyte cultures, the component mixture (free PLP, free LABL, 
and free HA) had a similar cytokine expression profile as that of the 
conjugated form (SAgAPLP:LABL). Perhaps a reason for this response 
is that the classical “2-signal” immune signaling is based on the 
presence of both antigen and “context” signal in the same time and 
space. This basic ex vivo screen may have a “containment” effect, 
placing both antigen and LABL in the same time and space artifi-
cially. If this assumption holds true, this may suggest that HA acts 
as a peptide “tether” in vivo to simply increase the local concentra-
tion of both peptides. Alternatively, covalent conjugation of PLP 
and LABL may deliver antigen and LABL above a threshold valency 
required to illicit an immune response.59,60 Interestingly, similar in 
vivo protection was observed in mice treated with an equivalent 
dose of 1:1 HAPLP:HALABL mixture or SAgAPLP:LABL; however, EAE sple-
nocytes given these treatments had very different cytokine expres-
sion levels (Figure 4). Further studies are needed to identify the 
mechanisms whereby SAgAPLP:LABL and the 1:1 HALABL:HAPLP mixture 
protect mice against EAE.
Conclusion
In this study, we explored the mechanisms of SAgAs as novel 
antigen-SIT for the treatment of EAE, a murine model of MS, by 
combining delivery of antigen with delivery of a peptide known 
to inhibit immune cell adhesion. The in vivo data showed that 
Figure 3 Cellular metabolism rates in experimental autoimmune 
encephalomyelitis (EAE) splenocytes harvested during disease remission 
(day 25) and retreated ex vivo. Primary splenocytes were isolated from 
EAE mice disease remission (day 25) and were treated ex vivo as indicated. 
Cells were then stimulated with 25 µmol/l proteolipid protein peptide 
(PLP; gray bars) or vehicle (media; black bars) for 120 hours and incubated 
with risazurin (75 µmol/l final). Fluorescence (560excitation/590emission) was 
determined 24 hours later (n = 4 mice per group). *Indicates significance 
(P < 0.05) from media treated, unstimulated (vehicle primed) splenocytes. 
HA, hyaluronic acid; HALABL, HA with grafted LABL peptide; HAPLP, HA with 
grafted PLP peptide; PBS, phosphate-buffered saline; SAgAPLP:LABL, soluble 
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Figure 4 Primary splenocytes were isolated from experimental autoimmune encephalomyelitis (EAE) mice treated with phosphate-buffered 
saline (PBS; control group) at the end of study (day 25). Splenocytes were stimulated with 25 µmol/l proteolipid protein peptide (PLP; gray bars) or 
vehicle (media; black bars) and cotreated with component mixture (2.5 µmol/l hyaluronic acid (HA), 25 µmol/l free PLP peptide, and 25 µl free LABL 
peptide), 2.5 µmol/l HA with grafted LABL peptide (HALABL), 2.5 µmol/l , HA with grafted PLP peptide (HAPLP), 1.25:1.25 µmol/l HALABL:HAPLP mixture, 
or 2.5 µmol/l soluble antigen array cografted with PLP and LABL peptides (SAgAPLP:LABL) for 120 hours. Levels of (a) Interleukin (IL)-2, (b) IL-4, (c) IL-5, 
(d) IL-6, (e) IL-13, (f) IL-17, (g) IL-22, and (h) tumor necrosis factor-α (TNF-α) in the cell culture supernatant were determined. Data are expressed as mean 
± SD from splenocytes isolated from four independent mice (n = 4). *Indicates statistical significance (P < 0.05) from unstimulated splenocytes treated 
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codelivery through conjugation of both antigenic peptide (PLP) 
and an ICAM-1 inhibitor (LABL) to HA, either along a heteropoly-
mer (SAgAPLP:LABL) or an equivalent combined dose of two homo-
polymers (HAPLP and HALABL), enhanced clinical score outcomes. 
Conversely, when tested ex vivo using splenocytes from EAE mice, 
cytokine profiles showed that as long as HA, PLP, and LABL were 
present in the sample, regardless of conjugation state, a response 
was generated. The ex vivo data showed a high dependence on 
the molecular characteristics of treatments while in vivo, the 
physics behind their copresentation was just as important.
These data confirm that in order to identify safer and more effica-
cious therapies to treat autoimmune diseases such as MS, we must 
understand the mechanisms whereby delivering a conjugated anti-
gen and a secondary “context” signal therapeutic inhibits disease. 
Furthermore, because codelivery of both antigen and a secondary 
“context” signal through separate homopolymers was effective at 
treating EAE, this therapeutic paradigm may ultimately be adapt-
able as a supplemental additive formulation to current antigen 
only therapeutics such as Copaxone (R) (myelin antigen derivative) 
and therapeutics such as TYSABRI (R) (surface receptor) inhibitor. 
Antigen-SIT combinations with secondary “context” signals or inhib-
itors needs to be further investigated to improve our understanding 




HA, with an average molecular weight of 16.9 kDa, was purchased from 
Lifecore Biomedical (Chaska, MN). Analytical grade acetonitrile and synthesis 
grade trifluoro acetic acid were purchased from Fisher Scientific (Waltham, 
MA). Research grade sodium acetate, acetic acid, 7-hydroxy-3H-phenox-
azin-3-one 10-oxide, and D2O were purchased from Sigma (St. Louis, MO). 
Complete Freund’s adjuvant and killed Mycobacterium tuberculosis strain 
H37RA were purchased from Difco (Sparks, MD). Water was provided by a 
Labconco (Kansas City, KS) Water PRO PS ultrapure water purification unit.
Peptide synthesis
Aminooxy peptides were synthesized using 9-fluorenylmethyloxycarbonyl–
protected amino acid chemistry on polyethylene glycol-polystyrene resins. 
The peptides synthesized were aminooxy-LABL (aminooxy-ITDGEATDSG, 
Ao-LABL), a ligand of ICAM-1 and aminooxy-PLP (aminooxy–HSLGKWLGHPDKF, 
Ao-PLP), an antigen derived from proteolipid protein amino acids 139–151 
(PLP137–151). Peptides were deprotected, cleaved from resin, and isolated 
by precipitation in ether. Purification was completed using preparatory HPLC 
followed by lyophilization. Peptide identity was verified, and purity/content 
was assessed using mass spectroscopy and analytical HPLC.
Reaction of aminooxy peptides to polymers
HA was dissolved in 20 mmol/l acetate buffer (pH 5.5 ± 0.1), and aminooxy 
reactive peptides were added. When both LABL and PLP peptides were used, 
each was weighed separately, dry powders were mixed, and then added 
simultaneously to reaction solution. After addition of the peptide(s), the 
reaction solution pH was adjusted back to 5.5 ± 0.1. Reaction solutions were 
stirred at 500 rpm using magnetic stir bars for ~16 hours. After the reaction, 
the SAgA (SAgAPLP:LABL) or HA-conjugate control (HAPLP, HALABL) products were 
purified by extensive dialysis to remove any unreacted peptide and were 
then lyophilized.
Gel permeation chromatography
The relative molecular weight of the HA and of the SAgAs was estimated 
using a Waters (Waters Corp., Milford, MA) 2695 Separation Module with 
column heater set at 25 °C, and samples were detected using Waters 2414 
refractive index detector and Waters 2489 UV/Vis and injection volume of 
50 μl. A tandem column setup of two Agilent (Agilent Technologies, Santa 
Clara, CA) Aquagel-OH 40 columns (Agilent) was used at a flow rate of 0.6 ml/
minute with isocratic elution in 0.1 mol/l ammonium acetate buffer pH 5.0 
with 0.25 mol/l NaCl for 45 minutes. Analysis was completed using Empower 
3 software suite (Waters Corp., Milford, MA).
High-performance liquid chromatography
Quantification of free peptide postreaction was accomplished by gra-
dient reversed phase HPLC (SHIMADZU, SHIMADZU Corp., Kyoto, KYT) 
using a Vydac HPLC protein and peptide C18 column. HPLC system was 
composed of an SCL-20A SHIMADZU system controller, LC-10AT VP 
SHIMADZU liquid chromatograph, SIL-10A XL SHIMADZU autoinjector set 
at 75 μl injection volume, DGU-14A SHIMADZU degasser, sample cooler, 
and SPD-10A SHIMADZU UV-vis detector (220 nm). A personal computer 
equipped with SHIMADZU class VP software controlled the HPLC-UV sys-
tem. Gradient elution was conducted at a constant flow of 1 ml/minute, 
from 100% A to 35% A (corresponding to 0% B to 65% B) over 50 minutes, 
followed by an isocratic elution at 75% B for 3 minutes. Mobile phase 
compositions were (A) acetonitrile-water (5:95) with 0.1% trifluoro acetic 
acid and (B) acetonitrile-water (90:10, v/v) with 0.1% trifluoro acetic acid. 
At the completion of each analysis, the cartridge was equilibrated at ini-
tial conditions of 1 ml/minute flow rate for 5 minutes with A.
Induction of EAE and therapeutic study
SJL/J (H-2s) female mice, 4–6 weeks old, were purchased from Harlan 
Laboratories (Indianapolis, IN) and housed under specified, pathogen-free 
conditions at The University of Kansas (Lawrence, KS). All protocols involv-
ing live mice were approved by the Institutional Animal Care and Use 
Committee. Mice were immunized subcutaneously (s.c.) with 200 mg of 
PLP139–151 in a 0.2-ml emulsion composed of equal volumes of PBS and 
complete Freund’s adjuvant containing killed M. tuberculosis strain H37RA 
(final concentration of 4 mg/ml; Difco). The PLP139–151/complete Freund’s 
adjuvant was administered to regions above the shoulders and the flanks 
(total of four sites; 50 μl at each injection site). In addition, 200 ng/100 μl 
of pertussis toxin (List Biological Laboratories, Campbell, CA) was injected 
intraperitoneally (i.p.) on the day of immunization (day 0) and 2 days postim-
munization. The mice received s.c. injections of each sample, equivalent to 
200 nmol PLP/100 μl (HALABL 200 nmol), based on peptide concentration val-
ues calculated using HPLC, on days 4, 7, and 10. Disease progression was 
evaluated blindly by the same observer using clinical scoring as follows: 0, 
no clinical signs of the disease; 1, tail weakness or limp tail; 2, paraparesis 
(weakness or incomplete paralysis of one or two hind limbs); 3, paraplegia 
(complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness 
or paralysis; and 5, moribund (mice were euthanized if they were found to be 
moribund). Body weight was also measured daily.
Splenocyte isolation and ex vivo treatment of splenocytes
Mouse spleens were resected 12 or 25 days postimmunization as experi-
mentally appropriate, passed through a wire mesh using the rubber end of 
a sterile 1-ml syringe plunger, and collected in 5 ml of RPMI 1640 media. The 
crude cellular extract was then centrifuged at 1,100g for 5 minutes, and the 
resulting cell pellet was resuspended in 3.5 ml of 1× Gey’s lysis solution and 
placed on ice for 3.5 minutes to lyse splenic red blood cells. The lysis reac-
tion was stopped by the addition of 10.5 ml of RPMI 1640 media contain-
ing 10% fetal bovine serum and was centrifuged at 1,100g for 5 minutes. 
The remaining cell pellet was resuspended in fresh media (RPMI 1640 media 
containing 10% FBS and 1% penicillin–streptomycin) and seeded in 96-well 
cell culture plates at a cell density of 1 × 106 cells/well in a final volume of 100 
µl. For in vitro rechallenge assays, splenocytes were then immediately stimu-
lated with 25 µmol/l PLP peptide or vehicle (RPMI media). For select studies, 
vehicle- and PLP-stimulated splenocytes were also cotreated with 2.5 µmol/l 
HALABL, 2.5 µmol/l HAPLP, a 1:1 mixture of 1.25 µmol/l HALABL and 1.25 µmol/l 
HAPLP, 2.5 µmol/l SAgAPLP:LABL, an equivalent mixture of noncovalently linked 
SAgA components (2.5 µmol/l HA, 25 µmol/l LABL, and 25 µmol/l PLP), or 
vehicle (RPMI media). Stimulated cell cultures were incubated for 120 hours 
at 37 °C in a CO2 (5%) incubator.
Measurement of in vitro cytokines and cellular metabolism
Cell culture supernatant levels of cytokines were determined by a commer-
cially available bead array ELISA kit and supporting Flow Cytomix Software 
(ebiosciences, San Diego, CA). Cell viability (metabolic capacity) was deter-
mined by a resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) assay. 
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Briefly, resazurin (75 µmol/l final) was added to splenocyte cultures and 
incubated for an additional 24 hours, and metabolic reductive capacity was 
determined by a change in fluorescence (560excitation/590emission). Background 
fluorescence was determined in sterile FBS, and resazurin containing RPMI 
media and was subtracted from each experimental read.
Statistical analysis
Statistical differences were determined by comparing treated groups with 
the negative control (PBS) for clinical disease score and body weight. Data 
were analyzed with a one- or two-way analysis of variance as experimentally 
appropriate followed by Fisher’s least significant difference post hoc test. A P 
value <0.05 (or 0.01) was considered the threshold of statistical significance. 
All analyses were performed using GraphPad Software (GraphPad Software, 
La Jolla, CA).
CONFlICT OF INTeReST
The authors declare no conflict of interest.
ACKNOWleDGMeNTS
We gratefully acknowledge support from the NIAID (R56AI091996). This work was also 
supported by grants from the National Center for Research Resources (5P20RR016475) 
and the National Institute of General Medical Sciences (8P20GM103418) from the 
National Institutes of Health, The Madison and Lila Self Graduate Fellowship (University 
of Kansas) and The Institute for Advancing Medical Innovation Graduate Fellowship 
(University of Kansas).
ReFeReNCeS
 1 Brück, W, Gold, R, Lund, BT, Oreja-Guevara, C, Prat, A, Spencer, CM et al. (2013). 
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 70: 
1315–1324.
 2 Lucchinetti, CF, Bruck, W and Lassmann, H (2004). Evidence for pathogenic heterogeneity 
in multiple sclerosis. Ann Neurol 56: 308.
 3 Ransohoff, RM and Brown, MA (2012). Innate immunity in the central nervous system.  
J Clin Invest 122: 1164–1171.
 4 Carson, MJ, Doose, JM, Melchior, B, Schmid, CD and Ploix, CC (2006). CNS immune 
privilege: hiding in plain sight. Immunol Rev 213: 48–65.
 5 Amor,  S, Puentes,  F, Baker,  D and van  der  Valk,  P (2010). Inflammation in 
neurodegenerative diseases. Immunology 129: 154–169.
 6 Wingerchuk, DM and Lucchinetti, CF (2007). Comparative immunopathogenesis of 
acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr 
Opin Neurol 20: 343–350.
 7 Bates, D (2011). Treatment effects of immunomodulatory therapies at different stages of 
multiple sclerosis in short-term trials. Neurology 76: S14–S25.
 8 Weiner, HL (2004). Multiple sclerosis is an inflammatory T-cell-mediated autoimmune 
disease. Arch Neurol 61: 1613–1615.
 9 Miller, SD, Turley, DM and Podojil, JR (2007). Antigen-specific tolerance strategies for the 
prevention and treatment of autoimmune disease. Nat Rev Immunol 7: 665–677.
 10 Dolgin, E (2010). The inverse of immunity. Nat Med 16: 740–743.
 11 Aharoni, R, Teitelbaum, D, Leitner, O, Meshorer, A, Sela, M and Arnon, R (2000). Specific Th2 
cells accumulate in the central nervous system of mice protected against experimental 
autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 97: 11472–11477.
 12 Senti, G, Prinz Vavricka, BM, Erdmann, I, Diaz, MI, Markus, R, McCormack, SJ et al. (2008). 
Intralymphatic allergen administration renders specific immunotherapy faster and safer: 
a randomized controlled trial. Proc Natl Acad Sci USA 105: 17908–17912.
 13 Steinman, L and Conlon, P (2001). Antigen specific immunotherapy of multiple sclerosis. 
J Clin Immunol 21: 93–98.
 14 Okuno, T, Nakatsuji, Y, Moriya, M, Nojima, S, Sakoda, S, Kumanogoh, A, et al. (2010). 
Multiple sclerosis (PP-038) [abstr.]. Int Immunol Meeting Abstracts 22: i148–i155.
 15 Kool, M, Pétrilli, V, De Smedt, T, Rolaz, A, Hammad, H, van Nimwegen, M et al. (2008). 
Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation 
of the NALP3 inflammasome. J Immunol 181: 3755–3759.
 16 Ahmed, N and Gottschalk, S (2009). How to design effective vaccines: lessons from an old 
success story. Expert Rev Vaccines 8: 543–546.
 17 Rolland, JM, Gardner, LM and O’Hehir, RE (2009). Allergen-related approaches to 
immunotherapy. Pharmacol Ther 121: 273–284.
 18 Lisak, RP, Zweiman, B, Blanchard, N and Rorke, LB (1983). Effect of treatment with 
Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic 
encephalomyelitis (EAE). J Neurol Sci 62: 281–293.
 19 Vickery, BP and Burks, AW (2009). Immunotherapy in the treatment of food allergy: focus 
on oral tolerance. Curr Opin Allergy Clin Immunol 9: 364–370.
 20 Vickery, BP, Scurlock, AM, Jones, SM and Burks, AW (2011). Mechanisms of immune 
tolerance relevant to food allergy. J Allergy Clin Immunol 127: 576–584.
 21 Senti, G, Crameri, R, Kuster, D, Johansen, F, Martinez-Gomez, JM, Graf, N et al. (2012). 
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. 
J Allergy Clin Immunol 129, 1290–1296.
 22 Sabatos-Peyton,  CA, Verhagen,  J and Wraith,  DC (2010). Antigen-specific 
immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 22, 609–615.
 23 Mossman, KD, Campi, G, Groves, JT and Dustin, ML (2005). Altered TCR signaling from 
geometrically repatterned immunological synapses. Science 310: 1191–1193.
 24 Hartman, NC, Nye, JA and Groves, JT (2009). Cluster size regulates protein sorting in the 
immunological synapse. Proc Natl Acad Sci USA 106: 12729–12734.
 25 Dustin, ML (2002). The immunological synapse. Arthritis Res 4(suppl. 3): S119–S125.
 26 Dustin, ML and Shaw, AS (1999). Costimulation: building an immunological synapse. 
Science 283: 649–650.
 27 Bromley, S, Iaboni, A, Davis, SJ, Whitty, A, Green, JM, Shaw, AS et al. (2001). The 
immunological synapse and CD28-CD80 interactions. Nat Immunol 2: 1159–1166.
 28 Kobayashi, N, Kobayashi, H, Gu, L, Malefyt, T and Siahaan, TJ (2007). Antigen-specific 
suppression of experimental autoimmune encephalomyelitis by a novel bifunctional 
peptide inhibitor. J Pharmacol Exp Ther 322: 879–886.
 29 Manikwar, P, Kiptoo, P, Badawi, AH, Büyüktimkin, B and Siahaan, TJ (2012). Antigen-
specific blocking of CD4-specific immunological synapse formation using BPI and 
current therapies for autoimmune diseases. Med Res Rev 32: 727–764.
 30 Yusuf-Makagiansar, H, Makagiansar,  IT, Hu, Y and Siahaan, TJ (2001). Synergistic 
inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction. 
Peptides 22: 1955–1962.
 31 Dustin, ML (2009). The cellular context of T cell signaling. Immunity 30: 482–492.
 32 Sant, AJ, Chaves, FA, Jenks, SA, Richards, KA, Menges, P, Weaver, JM et al. (2005). The 
relationship between immunodominance, DM editing, and the kinetic stability of MHC 
class II:peptide complexes. Immunol Rev 207: 261–278.
 33 Dintzis,  HM, Dintzis,  RZ and Vogelstein,  B (1976). Molecular determinants of 
immunogenicity: the immunon model of immune response. Proc Natl Acad Sci USA 73: 
3671–3675.
 34 Dixon, FJ and Kunkel, HG (1982). Advances in Immunology. 32: Academic Press, USA.
 35 Dintzis, RZ, Okajima, M, Middleton, MH, Greene, G and Dintzis, HM (1989). The 
immunogenicity of soluble haptenated polymers is determined by molecular mass and 
hapten valence. J Immunol 143: 1239–1244.
 36 Reim, JW, Symer, DE, Watson, DC, Dintzis, RZ and Dintzis, HM (1996). Low molecular 
weight antigen arrays delete high affinity memory B cells without affecting specific T-cell 
help. Mol Immunol 33: 1377–1388.
 37 Symer, DE, Reim, J, Dintzis, RZ, Voss, EW Jr and Dintzis, HM (1995). Durable elimination 
of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in 
vivo. J Immunol 155: 5608–5616.
 38 Sestak, J, Mullins, M, Northrup, L, Thati, S, Forrest, ML, Siahaan, TJ et al. (2013). Single-
step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional 
therapeutics for experimental autoimmune encephalomyelitis. J Control Release 168: 
334–340.
 39 Aranami, T and Yamamura, T (2008). Th17 Cells and autoimmune encephalomyelitis 
(EAE/MS). Allergol Int 57: 115–120.
 40 Kuchroo, VK, Greer, JM, Kaul, D, Ishioka, G, Franco, A, Sette, A et al. (1994). A single TCR 
antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a 
diverse T cell repertoire. J Immunol 153: 3326–3336.
 41 Stern, JN, Illés, Z, Reddy, J, Keskin, DB, Fridkis-Hareli, M, Kuchroo, VK et al. (2005). Peptide 
15-mers of defined sequence that substitute for random amino acid copolymers in 
amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 
102: 1620–1625.
 42 Margot, CD, Ford, ML and Evavold, BD (2005). Amelioration of established experimental 
autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid 
protein 139-151. J Immunol 174: 3352–3358.
 43 Samson, MF and Smilek, DE (1995). Reversal of acute experimental autoimmune 
encephalomyelitis and prevention of relapses by treatment with a myelin basic protein 
peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol 155: 
2737–2746.
 44 Vanderlugt, CL, Neville, KL, Nikcevich, KM, Eagar, TN, Bluestone, JA and Miller, SD (2000). 
Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing 
experimental autoimmune encephalomyelitis. J Immunol 164: 670–678.
 45 Smith, CE, Eagar, TN, Strominger, JL and Miller, SD (2005). Differential induction of 
IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of 
autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102: 9595–9600.
 46 Wang, C, Gold, BG, Kaler, LJ, Yu, X, Afentoulis, ME, Burrows, GG et al. (2006). Antigen-
specific therapy promotes repair of myelin and axonal damage in established EAE.  
J Neurochem 98: 1817–1827.
 47 Johnson, KP, Brooks, BR, Cohen, JA, Ford, CC, Goldstein, J, Lisak, RP et al. (1995). 
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting 
9
Codelivery of antigen and LABL for efficacy of SAgAs in EAE
JO Sestak et al.
Molecular Therapy — Methods & Clinical Development (2014) 14008© 2014 The American Society of Gene & Cell Therapy
multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled 
trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268–1276.
 48 Blanchette, F and Neuhaus, O (2008). Glatiramer acetate: evidence for a dual mechanism 
of action. J Neurol 255(suppl. 1): 26–36.
 49 Neuhaus, O, Farina, C, Wekerle, H and Hohlfeld, R (2001). Mechanisms of action of 
glatiramer acetate in multiple sclerosis. Neurology 56: 702–708.
 50 Perrin, PJ, June, CH, Maldonado, JH, Ratts, RB and Racke, MK (1999). Blockade of CD28 
during in vitro activation of encephalitogenic T cells or after disease onset ameliorates 
experimental autoimmune encephalomyelitis. J Immunol 163: 1704–1710.
 51 Gerritse, K, Laman, JD, Noelle, RJ, Aruffo, A, Ledbetter, JA, Boersma, WJ et al. (1996). 
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple 
sclerosis. Proc Natl Acad Sci USA 93: 2499–2504.
 52 Langer-Gould, A, Atlas, SW, Green, AJ, Bollen, AW and Pelletier, D (2005). Progressive 
multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 
375–381.
 53 Ridwan, R, Kiptoo, P, Kobayashi, N, Weir, S, Hughes, M, Williams, T et al. (2010). 
Antigen-specific suppression of experimental autoimmune encephalomyelitis by a 
novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics.  
J Pharmacol Exp Ther 332: 1136–1145.
 54 Kang, Y, Xu, L, Wang, B, Chen, A and Zheng, G (2008). Cutting edge: immunosuppressant 
as adjuvant for tolerogenic immunization. J Immunol 180: 5172–5176.
 55 Badawi, AH, Kiptoo, P, Wang, WT, Choi, IY, Lee, P, Vines, CM et al. (2012). Suppression of 
EAE and prevention of blood–brain barrier breakdown after vaccination with novel 
bifunctional peptide inhibitor. Neuropharmacology 62: 1874–1881.
 56 Manikwar, P, Büyüktimkin, B, Kiptoo, P, Badawi, AH, Galeva, NA, Williams, TD et al. 
(2012). I-domain-antigen conjugate (IDAC) for delivering antigenic peptides to 
|APC: synthesis, characterization, and in vivo EAE suppression. Bioconjug Chem 23: 
509–517.
 57 Brod, SA, Marshall, GD Jr, Henninger, EM, Sriram, S, Khan, M and Wolinsky, JS (1996). 
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases 
interleukin-6 production in multiple sclerosis. Neurology 46: 1633–1638.
 58 Neurath,  MF and Finotto,  S (2011). IL-6 signaling in autoimmunity, chronic 
inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 
83–89.
 59 Kiessling, LL (2010). Decoding signals with chemical biology. ACS Chem Biol 5: 1–2.
 60 Puffer, EB, Pontrello, JK, Hollenbeck, JJ, Kink, JA and Kiessling, LL (2007). Activating B cell 
signaling with defined multivalent ligands. ACS Chem Biol 2: 252–262.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivative Works 3.0 License. To view a copy of 
this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)
